F-14413

F-14413
Clinical data
Other namesF14413; 5-Fluoro-methoxyidazoxan
Routes of
administration
Unspecified
Drug classα2-Adrenergic receptor antagonist or inverse agonist
ATC code
  • None
Identifiers
  • 2-[(2S)-5-fluoro-2-methoxy-3H-1,4-benzodioxin-2-yl]-4,5-dihydro-1H-imidazole
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H13FN2O3
Molar mass252.245 g·mol−1
3D model (JSmol)
  • CO[C@@]1(COC2=C(O1)C=CC=C2F)C3=NCCN3
  • InChI=1S/C12H13FN2O3/c1-16-12(11-14-5-6-15-11)7-17-10-8(13)3-2-4-9(10)18-12/h2-4H,5-7H2,1H3,(H,14,15)/t12-/m1/s1
  • Key:YGKDKIOEXKAIES-GFCCVEGCSA-N

F-14413, also known as 5-fluoro-methoxyidazoxan, is an α2-adrenergic receptor antagonist or inverse agonist which was under development for the treatment of Alzheimer's disease and Parkinson's disease in France but was never marketed. It is a derivative of idazoxan. The drug's route of administration was unspecified. It is said to be potent and highly selective as an α2-adrenergic receptor modulator. F-14413 was under development by Pierre Fabre. It reached the preclinical research stage of development prior to its discontinuation. F-14413 was first described in the scientific literature by 2001, while its latest developmental update was in 2003.

See also